Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Octreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 13/20 | 1.00 |
| ▸ | SSTR5 known ✓ | P35346 | 13/20 | 1.00 |
| ▸ | SSTR4 known ✓ | P31391 | 9/20 | 1.00 |
| ▸ | SSTR3 known ✓ | P32745 | 5/20 | 0.88 |
| ▸ | SSTR1 known ✓ | P30872 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Octreotide SCHEMBL17404479 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL19232283 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL18823378 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404481 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL15856937 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL17404626 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL23424109 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL15932939 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL21944070 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 | |
| Octreotide SCHEMBL10044649 | 1.00 | SSTR2 (1.00) | SSTR2SSTR5SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2023-03-23 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087806-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | SSTR2 3804/4885SSTR5 4137/4885SSTR4 4377/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | SSTR2 3804/4885SSTR5 4137/4885SSTR4 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.